NASDAQ:MDWD MediWound (MDWD) Stock Price, News & Analysis → the most reliable asset on earth is making a comeback (From DTI) (Ad) Free MDWD Stock Alerts $14.31 -0.79 (-5.23%) (As of 03:52 PM ET) Add Compare Share Share Today's Range$14.21▼$15.3550-Day Range$11.25▼$17.1152-Week Range$7.10▼$17.25Volume151,455 shsAverage Volume63,032 shsMarket Capitalization$135.80 millionP/E RatioN/ADividend YieldN/APrice Target$32.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get MediWound alerts: Email Address MediWound MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside123.6% Upside$32.00 Price TargetShort InterestHealthy1.63% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.54Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.84) to ($1.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.08 out of 5 starsMedical Sector584th out of 938 stocksMedicinals & Botanicals Industry4th out of 11 stocks 3.5 Analyst's Opinion Consensus RatingMediWound has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.00, MediWound has a forecasted upside of 123.6% from its current price of $14.31.Amount of Analyst CoverageMediWound has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.63% of the float of MediWound has been sold short.Short Interest Ratio / Days to CoverMediWound has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MediWound has recently increased by 99.87%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMediWound does not currently pay a dividend.Dividend GrowthMediWound does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MDWD. Previous Next 2.5 News and Social Media Coverage News SentimentMediWound has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for MediWound this week, compared to 1 article on an average week.MarketBeat Follows6 people have added MediWound to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MediWound insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.20% of the stock of MediWound is held by insiders.Percentage Held by Institutions46.83% of the stock of MediWound is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MediWound are expected to grow in the coming year, from ($1.84) to ($1.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MediWound is -18.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MediWound is -18.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMediWound has a P/B Ratio of 4.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) About MediWound Stock (NASDAQ:MDWD)MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.Read More MDWD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDWD Stock News HeadlinesMarch 24, 2024 | finance.yahoo.comMediWound Ltd. (NASDAQ:MDWD) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?March 23, 2024 | seekingalpha.comMediWound Ltd. (MDWD) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…March 23, 2024 | americanbankingnews.comMediWound's (MDWD) Buy Rating Reaffirmed at HC WainwrightMarch 23, 2024 | americanbankingnews.comMediWound (NASDAQ:MDWD) Upgraded by StockNews.com to HoldMarch 21, 2024 | markets.businessinsider.comMediwound Poised for Growth: A Strong Buy Recommendation Amidst Promising Prospects and Strategic ExpansionMarch 21, 2024 | investorplace.comMDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q4 2023March 21, 2024 | msn.comMediWound reports mixed Q4 results; initiates FY24 outlookMarch 28, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.March 21, 2024 | chron.comMediWound: Q4 Earnings SnapshotMarch 21, 2024 | globenewswire.comMediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company UpdateMarch 20, 2024 | msn.comMediWound Q4 2023 Earnings PreviewMarch 19, 2024 | americanbankingnews.comMediWound (MDWD) Set to Announce Earnings on ThursdayMarch 14, 2024 | globenewswire.comMediWound to Report Fourth Quarter and Full Year 2023 Financial ResultsMarch 7, 2024 | finance.yahoo.comRetail investors who hold 38% of MediWound Ltd. (NASDAQ:MDWD) gained 15%, institutions profited as wellFebruary 23, 2024 | msn.comNexobrid: A revolutionary treatment for burns to treat patients in few hoursFebruary 12, 2024 | marketwatch.comMediWound Shares Climb on Positive Data for EscharExFebruary 12, 2024 | markets.businessinsider.comMediWound Reports Positive Results In Head-to-head Comparison Of EscharEx Vs SANTYLFebruary 12, 2024 | finance.yahoo.comMediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled StudyFebruary 5, 2024 | finance.yahoo.comMediWound to Participate in Two Upcoming Investor ConferencesJanuary 15, 2024 | finance.yahoo.comMediWound (MDWD)'s Technical Outlook is Bright After Key Golden CrossJanuary 12, 2024 | markets.businessinsider.comMediwound Poised for Growth: Buy Rating Affirmed Amidst FDA Progress, Revenue Forecasts, and Expansion PotentialJanuary 9, 2024 | finance.yahoo.comWall Street Analysts Think MediWound (MDWD) Could Surge 134.77%: Read This Before Placing a BetJanuary 9, 2024 | markets.businessinsider.comMediWound: FDA To Review NexoBrid SBLA For Removal Of Eschar In Pediatric PatientsJanuary 9, 2024 | msn.comFDA accepts MediWound application for NexoBrid pediatric approvalJanuary 9, 2024 | finance.yahoo.comMediWound (MDWD): Strong Industry, Solid Earnings Estimate RevisionsJanuary 9, 2024 | finance.yahoo.comMediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal BurnsSee More Headlines Receive MDWD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/21/2023Today3/28/2024Next Earnings (Estimated)6/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medicinals & botanicals Sub-IndustryN/A Current SymbolNASDAQ:MDWD CUSIPN/A CIK1593984 Webwww.mediwound.com Phone972779714100Fax972-77-971-4111Employees100Year Founded2001Price Target and Rating Average Stock Price Target$32.00 High Stock Price Target$36.00 Low Stock Price Target$28.00 Potential Upside/Downside+123.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,720,000.00 Net Margins-35.94% Pretax Margin-34.95% Return on Equity-20.22% Return on Assets-10.08% Debt Debt-to-Equity RatioN/A Current Ratio4.59 Quick Ratio4.33 Sales & Book Value Annual Sales$18.69 million Price / Sales7.29 Cash FlowN/A Price / Cash FlowN/A Book Value$3.43 per share Price / Book4.18Miscellaneous Outstanding Shares9,490,000Free Float8,619,000Market Cap$136.18 million OptionableOptionable Beta0.94 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMs. Hani Luxenburg (Age 51)Chief Financial Officer Comp: $235kMr. Ofer Gonen B.Sc. (Age 51)Chief Executive Officer Comp: $485kDr. Lior Rosenberg M.D. (Age 78)Co-Founder Comp: $727kDr. Shmulik Hess Ph.D. (Age 51)COO & Chief Commercial Officer Mr. Yaron Meyer Adv. (Age 45)Executive VP, General Counsel & Corporate Secretary Comp: $240kMr. Barry J. Wolfenson (Age 57)Executive Vice President of Strategy & Corporate Development Dr. Ety Klinger MBA (Age 62)Ph.D., Chief Research & Development Officer Comp: $393kDr. Robert J. Snyder CWS (Age 74)D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc., Chief Medical Officer More ExecutivesKey CompetitorsTelomir PharmaceuticalsNASDAQ:TELOClearside BiomedicalNASDAQ:CLSDImmunicNASDAQ:IMUXTheseus PharmaceuticalsNASDAQ:THRXGlycoMimeticsNASDAQ:GLYCView All CompetitorsInstitutional OwnershipSphera Funds Management LTD.Sold 59,553 shares on 2/15/2024Ownership: 0.532%Citadel Advisors LLCBought 16,698 shares on 2/15/2024Ownership: 0.181%MGO One Seven LLCBought 12,158 shares on 2/14/2024Ownership: 0.132%Pathstone Holdings LLCBought 10,874 shares on 2/14/2024Ownership: 0.118%Yelin Lapidot Holdings Management Ltd.Bought 39,348 shares on 2/12/2024Ownership: 1.363%View All Institutional Transactions MDWD Stock Analysis - Frequently Asked Questions Should I buy or sell MediWound stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MDWD shares. View MDWD analyst ratings or view top-rated stocks. What is MediWound's stock price target for 2024? 2 analysts have issued 12-month price targets for MediWound's shares. Their MDWD share price targets range from $28.00 to $36.00. On average, they predict the company's stock price to reach $32.00 in the next year. This suggests a possible upside of 123.6% from the stock's current price. View analysts price targets for MDWD or view top-rated stocks among Wall Street analysts. How have MDWD shares performed in 2024? MediWound's stock was trading at $10.17 on January 1st, 2024. Since then, MDWD stock has increased by 40.7% and is now trading at $14.31. View the best growth stocks for 2024 here. Are investors shorting MediWound? MediWound saw a increase in short interest in March. As of March 15th, there was short interest totaling 153,300 shares, an increase of 99.9% from the February 29th total of 76,700 shares. Based on an average daily volume of 58,700 shares, the days-to-cover ratio is currently 2.6 days. Approximately 1.6% of the shares of the company are sold short. View MediWound's Short Interest. When is MediWound's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 4th 2024. View our MDWD earnings forecast. How were MediWound's earnings last quarter? MediWound Ltd. (NASDAQ:MDWD) posted its earnings results on Tuesday, November, 21st. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.21. The biopharmaceutical company earned $4.78 million during the quarter, compared to the consensus estimate of $4.73 million. MediWound had a negative net margin of 35.94% and a negative trailing twelve-month return on equity of 20.22%. During the same quarter in the prior year, the firm posted ($0.91) EPS. When did MediWound's stock split? MediWound's stock reverse split on the morning of Tuesday, December 20th 2022. The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. What other stocks do shareholders of MediWound own? Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC). Who are MediWound's major shareholders? MediWound's stock is owned by many different institutional and retail investors. Top institutional shareholders include Yelin Lapidot Holdings Management Ltd. (1.36%), Sargent Investment Group LLC (1.19%), Silverberg Bernstein Capital Management LLC (0.86%), Sphera Funds Management LTD. (0.53%), Essex Investment Management Co. LLC (0.42%) and Citadel Advisors LLC (0.18%). How do I buy shares of MediWound? Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MDWD) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediWound Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.